Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

Asif, Muhammad; Amir, Muhammad; Hussain, Abrar; Achakzai, Niaz M; Pushparaj, Peter Natesan; Rasool, Mahmood

doi:10.1097/md.0000000000029660

Cited by 5 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17,18 Nevertheless, no drug or vaccine has shown to be specific and/or effective to treat SARS-CoV-2 up to now. 19,20 Another promising approach consists to investigate natural resources including medicinal plants. Many phytochemicals have indeed been reported to possess antiviral properties.…”

Section: Introductionmentioning

confidence: 99%

Molecular Docking and Pharmacokinetics Studies of Syzygium aromaticum Compounds as Potential SARS-CoV-2 Main Protease Inhibitors

2023

TJNPR

View full text Add to dashboard Cite

The current outbreak of the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2), is the major matter of public health concern given its worldwide impact on human life. Despite the research efforts, no effective drug is available for the treatment of this pandemic so far. In the present study, bioactive compounds derived from Syzygium aromaticum were screened for their inhibitor potency against SARS-CoV-2 main protease (Mpro) using molecular docking. The analysis revealed that five out of the twenty phytocompounds tested, namely campesterol, stigmasterol, crategolic acid, oleanolic acid and bicornin displayed the highest binding affinity scores against the target protein (-7.7, -7.9, -8.4, -8.5 and -9.2 kcal/mol, respectively). The drug-like and ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) predictions showed that these ligands, except bicornin, fall within the Lipinski's rule of five, and have a good pharmacokinetic profile. Our findings suggest therefore that these natural molecules could be considered as potential therapeutic drugs against SARS-CoV-2.

show abstract

Section: Introductionmentioning

confidence: 99%

Molecular Docking and Pharmacokinetics Studies of Syzygium aromaticum Compounds as Potential SARS-CoV-2 Main Protease Inhibitors

2023

TJNPR

View full text Add to dashboard Cite

show abstract

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

Bao

Gao

et al. 2023

Ann Hematol

View full text Add to dashboard Cite

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B

Tian

2023

Front. Oncol.

View full text Add to dashboard Cite

The application of immunosuppressive agents and targeted drugs has opened a novel approach for the treatment of hematological tumors, and the application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia is one of the landmark breakthroughs that has considerably improved the prognosis of CML patients. However, with the extensive use of TKI, the co-infection of CML patients has become increasingly apparent, especially regarding infectious diseases such as hepatitis B and COVID-19. The underlying mechanism may be related to the inhibition of the immune function by TKI. Poor management, including disease progression due to the infectious disease or TKI dose reduction or discontinuation, may lead to adverse clinical outcomes and can even be life-threatening. Therefore, this review principally provides an overview of the pathogenesis and standardized management principles of CML patients with comorbid COVID-19 or hepatitis B in order to improve clinicians’ awareness of the risks so as to more effectively diagnose and treat CML and improve the survival rate and quality of life of patients. In the past two decades, owing to the advent of imatinib, chronic myeloid leukemia (CML) has transformed into a chronic controllable disease, and even treatment-free remission can be anticipated. Earlier studies have indicated that tyrosine kinase inhibitor (TKI) exerts a peculiar inhibitory effect on the body’s immune function. Therefore, with the widespread application of TKI, more and more attention has been paid to the comorbidity of infectious diseases in CML patients, especially in patients with progressive disease or non-remission. Despite some studies revealing that the proportion and severity of SARS-CoV-2 infection in CML patients receiving TKI treatment are lower than in patients with other hematological malignancies, CML patients with stable disease are still recommended to be vaccinated against SARS-CoV-2, while TKI may or may not be discontinued. Meanwhile, the management of CML patients during the epidemic of coronavirus disease 2019 (COVID-19) still necessitates further discussion. This article also provides an overview of TKI-related hepatitis B reactivation. If not managed, patients may face adverse consequences such as hepatitis B reactivation-related hepatitis, liver failure, and progression of CML after forced withdrawal of medication. Therefore, this review aimed to comprehensively describe the management of CML patients with comorbid COVID-19, the pathogenesis of hepatitis B reactivation, the indicated population for prophylactic antiviral therapy, the time of antiviral drug discontinuation, and drug selection.

show abstract

Role of tyrosine kinase inhibitor in chronic myeloid leukemia patients with SARS-CoV-2 infection: A narrative Review

Cited by 5 publications

References 72 publications

Molecular Docking and Pharmacokinetics Studies of Syzygium aromaticum Compounds as Potential SARS-CoV-2 Main Protease Inhibitors

Molecular Docking and Pharmacokinetics Studies of Syzygium aromaticum Compounds as Potential SARS-CoV-2 Main Protease Inhibitors

Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era

Management of chronic myelogenous leukemia with COVID-19 and hepatitis B

Contact Info

Product

Resources

About